Literature DB >> 11602608

Ligand exchange of major histocompatibility complex class II proteins is triggered by H-bond donor groups of small molecules.

Kirsten Falk1, Julie M Lau, Laura Santambrogio, Viviana Marin Esteban, Fabiola Puentes, Olaf Rotzschke, Jack L Strominger.   

Abstract

Hydrogen bonds (H-bonds) are crucial for the stability of the peptide-major histocompatibility complex (MHC) complex. In particular, the H-bonds formed between the peptide ligand and the MHC class II binding site appear to have a great influence on the half-life of the complex. Here we show that functional groups with the capacity to disrupt hydrogen bonds (e.g. -OH) can efficiently catalyze ligand exchange reactions on HLA-DR molecules. In conjunction with simple carrier molecules (such as propyl or benzyl residues), they trigger the release of low affinity ligands, which permits the rapid binding of peptides with higher affinity. Similar to HLA-DM, these compounds are able to influence the MHC class II ligand repertoire. In contrast to HLA-DM, however, these simple small molecules are still active at neutral pH. Under physiological conditions, they increase the number of "peptide-receptive" MHC class II molecules and facilitate exogenous peptide loading of dendritic cells. The drastic acceleration of the ligand exchange on these antigen presenting cells suggests that, in general, availability of H-bond donors in the extracellular milieu controls the rate of MHC class II ligand exchange reactions on the cell surface. These molecules may therefore be extremely useful for the loading of antigens onto dendritic cells for therapeutic purposes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602608     DOI: 10.1074/jbc.M109098200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

1.  A potential nanobiotechnology platform based on infectious bursal disease subviral particles.

Authors:  Omid Taghavian; Manoj K Mandal; Nicole F Steinmetz; Stefan Rasche; Holger Spiegel; Rainer Fischer; Stefan Schillberg
Journal:  RSC Adv       Date:  2012-01-09       Impact factor: 3.361

2.  Small molecules that enhance the catalytic efficiency of HLA-DM.

Authors:  Melissa J Nicholson; Babak Moradi; Nilufer P Seth; Xuechao Xing; Gregory D Cuny; Ross L Stein; Kai W Wucherpfennig
Journal:  J Immunol       Date:  2006-04-01       Impact factor: 5.422

3.  A pH-sensitive histidine residue as control element for ligand release from HLA-DR molecules.

Authors:  Olaf Rötzschke; Julie M Lau; Maria Hofstätter; Kirsten Falk; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-05       Impact factor: 11.205

4.  The lymph as a pool of self-antigens.

Authors:  Cristina C Clement; Olaf Rotzschke; Laura Santambrogio
Journal:  Trends Immunol       Date:  2010-12-01       Impact factor: 16.687

5.  Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs.

Authors:  Waqasuddin Khan
Journal:  J Comput Aided Mol Des       Date:  2010-11-30       Impact factor: 3.686

Review 6.  On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes.

Authors:  Robert Busch; Alessandra De Riva; Andreas V Hadjinicolaou; Wei Jiang; Tieying Hou; Elizabeth D Mellins
Journal:  Expert Rev Mol Med       Date:  2012-07-06       Impact factor: 5.600

7.  Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Authors:  Jacques Thibodeau; Marie-Claude Bourgeois-Daigneault; Réjean Lapointe
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

Review 8.  On Peptides and Altered Peptide Ligands: From Origin, Mode of Action and Design to Clinical Application (Immunotherapy).

Authors:  Martín Candia; Bernhard Kratzer; Winfried F Pickl
Journal:  Int Arch Allergy Immunol       Date:  2016-09-20       Impact factor: 2.749

9.  Enhancement of tumour-specific immune responses in vivo by 'MHC loading-enhancer' (MLE).

Authors:  Katharina Dickhaut; Sabine Hoepner; Jamina Eckhard; Karl-Heinz Wiesmueller; Luise Schindler; Guenther Jung; Kirsten Falk; Olaf Roetzschke
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

10.  Anchor side chains of short peptide fragments trigger ligand-exchange of class II MHC molecules.

Authors:  Shashank Gupta; Sabine Höpner; Bernd Rupp; Sebastian Günther; Katharina Dickhaut; Noopur Agarwal; M Cristina Cardoso; Ronald Kühne; Karl-Heinz Wiesmüller; Günther Jung; Kirsten Falk; Olaf Rötzschke
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.